Fuzheng Huayu capsule belongs to the second-class protected varieties of national traditional Chinese medicine

On July 22, 2016, Fuzheng Huayu capsule, a compound traditional Chinese medicine independently developed by the company for the treatment of liver fibrosis, was approved by the State Food and Drug Administration (No. 125 in 2016) and became a national secondary protection variety of traditional Chinese medicine.


Since its listing in 2002, Fuzheng Huayu capsule has been in clinical application for more than 10 years, with accurate efficacy and reliable safety, and has won many awards from the Country and Shanghai province. Its theoretical research won the second prize of the "National Science and Technology Progress Award", its main patent won the Chinese Patent Excellence Award, and it is also a clinical drug recommended by the "National Guide for the Diagnosis and Treatment of Liver Fibrosis Combined with Traditional Chinese and Western Medicine". In September 2013, the company completed a phase II clinical trial of Fuzheng Huayu tablet in the treatment of chronic hepatitis C liver fibrosis in the United States.